Safety and immunogenicity of the recombinant mycobacterium bovis BCG vaccine VPM1002 in HIV-unexposed newborn infants in South Africa

Clinical and Vaccine Immunology

Volumn 24, Issue 2, 2017, Pages

  Loxton, André G ^a   Knaul, Julia K ^b   Grode, Leander ^b   Gutschmidt, Andrea ^a   Meller, Christiane ^b   Eisele, Bernd ^b   Johnstone, Hilary ^c   Van Der Spuy, Gian ^a   Maertzdorf, Jeroen ^d   Kaufmann, Stefan H E ^d   Hesseling, Anneke C ^a   Walzl, Gerhard ^a   Cotton, Mark F ^a  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b Vakzine Projekt Management GmbH   (Belgium)

^c HJ Clinical Trials Consultancy CC   (South Africa)

^d MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

Author keywords

HIVunexposed; IL 17; Immunogenicity; Newborn; Recombinant; Recombinant BCG; Safety; Vaccines; VPM1002; Whole blood assay

Indexed keywords

BCG VACCINE; CD8 ANTIGEN; INTERLEUKIN 17; UNCLASSIFIED DRUG; VPM 1002; RECOMBINANT VACCINE;

ADVERSE DRUG REACTION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; MALE; MYCOBACTERIUM BOVIS BCG; NEWBORN; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TUBERCULOSIS; VACCINE IMMUNOGENICITY; ABSCESS; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETICS; IMMUNOLOGY; INCIDENCE; PATHOLOGY; SOUTH AFRICA; TREATMENT OUTCOME;

ABSCESS; BCG VACCINE; CD8-POSITIVE T-LYMPHOCYTES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INCIDENCE; INFANT, NEWBORN; MALE; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; VACCINES, SYNTHETIC;

EID: 85014834049     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00439-16     Document Type: Article

References (69)

1. World Health Organization. 2016. Global tuberculosis report-2015. World Health Organization, Geneva, Switzerland.
2. Heyns L, Gie RP, Goussard P, Beyers N, Warren RM, Marais BJ. 2006. Nosocomial transmission of Mycobacterium tuberculosis in kangaroo mother care units: a risk in tuberculosis-endemic areas. Acta Paediatr 95:535-539. https://doi.org/10.1080/08035250600636560.
3. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, Enarson DA, Donald PR, Beyers N. 2004. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 8:392-402.
4. Vanden DK, Persson A, Marais BJ, Fink PJ, Urdahl KB. 2013. Immune vulnerability of infants to tuberculosis. Clin Dev Immunol 2013:781320. https://doi.org/10.1155/2013/781320.
5. Hesseling AC, Johnson LF, Jaspan H, Cotton MF, Whitelaw A, Schaaf HS, Fine PE, Eley BS, Marais BJ, Nuttall J, Beyers N, Godfrey-Faussett P. 2009. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bull World Health Organ 87:505-511. https://doi.org/10.2471/BLT.08.055657.
6. Marais BJ. 2004. Childhood tuberculosis: reflections from the front line. Pediatr Ann 33:695-698. https://doi.org/10.3928/0090-4481-20041001-13.
7. Swaminathan S, Ramachandran G. 2015. Challenges in childhood tuber-culosis. Clin Pharmacol Ther 98:240-244. https://doi.org/10.1002/cpt.175.
8. Wiseman CA, Gie RP, Starke JR, Schaaf HS, Donald PR, Cotton MF, Hesseling AC. 2012. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr Infect Dis J 31:347-352. https://doi.org/10.1097/INF.0b013e318243e27b.
9. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. 2014. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modeling study. Lancet Glob Health 2:e453-e459. https://doi.org/10.1016/S2214-109X(14)70245-1.
10. Statens Serum Institut. 2007. SmPC of BCG 1331 SSI: summary of product characteristics. Statens Serum Institut, Copenhagen, Denmark.
11. Serum Institute of India Pvt, Ltd. 2016. SII BCG vaccine. Serum Institute of India Pvt, Ltd, Pune, India.
12. Trunz BB, Fine P, Dye C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:1173-1180. https://doi.org/10.1016/S0140-6736(06)68507-3.
13. van Well GT, Paes BF, Terwee CB, Springer P, Roord JJ, Donald PR, van Furth AM, Schoeman JF. 2009. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics 123:e1-e8. https://doi.org/10.1542/peds.2008-1353.
14. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, Sterne JA. 2014. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58:470-480. https://doi.org/10.1093/cid/cit790.
15. Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P. 2016. Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study. Lancet Infect Dis 16:219-226. https://doi.org/10.1016/S1473-3099(15)00400-4.
16. Bonifachich E, Chort M, Astigarraga A, Diaz N, Brunet B, Pezzotto SM, Bottasso O. 2006. Protective effect of bacillus Calmette-Guerin (BCG) vaccination in children with extra-pulmonary tuberculosis, but not the pulmonary disease: a case-control study in Rosario, Argentina. Vaccine 24:2894-2899. https://doi.org/10.1016/j.vaccine.2005.12.044.
17. Zodpey SP, Shrikhande SN, Maldhure BR, Vasudeo ND, Kulkarni SW. 1998. Effectiveness of bacillus Calmette-Guerin (BCG) vaccination in the prevention of childhood pulmonary tuberculosis: a case control study in Nagpur, India. Southeast Asian J Trop Med Public Health 29:285-288.
18. Marais BJ, Seddon JA, Detjen AK, van der Werf MJ, Grzemska M, Hessel-ing AC, Curtis N, Graham SM, WHO Child TB Subgroup. 2016. Interrupted BCG vaccination is a major threat to global child health. Lancet Respir Med 4:251-253. https://doi.org/10.1016/S2213-2600(16)00099-0.
19. Jasenosky LD, Scriba TJ, Hanekom WA, Goldfeld AE. 2015. T cells and adaptive immunity to Mycobacterium tuberculosis in humans. Immunol Rev 264:74-87. https://doi.org/10.1111/imr.12274.
20. Lin PL, Flynn JL. 2015. CD8 T cells and Mycobacterium tuberculosis infection. Semin Immunopathol 37:239-249. https://doi.org/10.1007/s00281-015-0490-8.
21. da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP. 2014. Recom-binant BCG: innovations on an old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol 5:152. https://doi.org/10.3389/fimmu.2014.00152.
22. Lyadova IV, Panteleev AV. 2015. Th1 and Th17 cells in tuberculosis: protection, pathology, and biomarkers. Mediators Inflamm 2015:854507. https://doi.org/10.1155/2015/854507.
23. + T cells. Infect Immun 55:2037-2041.
24. + T cell response. J Immunol 177:5647-5651. https://doi.org/10.4049/jimmunol.177.8.5647.
25. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, Snell L, Mangtani P, Adetifa I, Lalvani A, Abubakar I. 2014. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. BMJ 349:g4643. https://doi.org/10.1136/bmj.g4643.
26. Jason J, Archibald LK, Nwanyanwu OC, Kazembe PN, Chatt JA, Norton E, Dobbie H, Jarvis WR. 2002. Clinical and immune impact of Mycobacterium bovis BCG vaccination scarring. Infect Immun 70:6188-6195. https://doi.org/10.1128/IAI.70.11.6188-6195.2002.
27. Schaible UE, Winau F, Sieling PA, Fischer K, Collins HL, Hagens K, Modlin RL, Brinkmann V, Kaufmann SH. 2003. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis. Nat Med 9:1039-1046. https://doi.org/10.1038/nm906.
28. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser EA, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, van Soolingen D, Raupach B, Kaufmann SH. 2005. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115: 2472-2479. https://doi.org/10.1172/JCI24617.
29. Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SH. 1998. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc Natl Acad Sci USA 95:5299-5304. https://doi.org/10.1073/pnas.95.9.5299.
30. + T cells. Vaccine 30:7608-7614. https://doi.org/10.1016/j.vaccine.2012.10.031.
31. Saiga H, Nieuwenhuizen N, Gengenbacher M, Koehler AB, Schuerer S, Moura-Alves P, Wagner I, Mollenkopf HJ, Dorhoi A, Kaufmann SH. 2015. The recombinant BCG ΔureC:hly vaccine targets the AIM2 inflam-masome to induce autophagy and inflammation. J Infect Dis 211: 1831-1841. https://doi.org/10.1093/infdis/jiu675.
32. Kaufmann SH, Cotton MF, Eisele B, Gengenbacher M, Grode L, Hesseling AC, Walzl G. 2014. The BCG replacement vaccine VPM1002: from drawing board to clinical trial. Expert Rev Vaccines 13:619-630. https://doi.org/10.1586/14760584.2014.905746.
33. Winau F, Weber S, Sad S, de Diego J, Hoops SL, Breiden B, Sandhoff K, Brinkmann V, Kaufmann SH, Schaible UE. 2006. Apoptotic vesicles crossprime CD8 T cells and protect against tuberculosis. Immunity 24: 105-117. https://doi.org/10.1016/j.immuni.2005.12.001.
34. + T cells are responsible for the recombinant bacillus Calmette-Guerin ΔureC:hly vaccine's superior protection against tuberculosis. J Infect Dis 210:1928-1937. https://doi.org/10.1093/infdis/jiu347.
35. + induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204:1573-1584. https://doi.org/10.1093/infdis/jir592.
36. Casanova JL, Blanche S, Emile JF, Jouanguy E, Lamhamedi S, Altare F, Stéphan JL, Bernaudin F, Bordigoni P, Turck D, Lachaux A Albertini M, Bourrillon A, Dommergues JP, Pocidalo MA, Le Deist F, Gaillard JL, Griscelli C, Fischer A. 1996. Idiopathic disseminated bacillus Calmette-Guerin infection: a French national retrospective study. Pediatrics 98:774-778.
37. Hesseling AC, Cotton MF, Jennings T, Whitelaw A, Johnson LF, Eley B, Roux P, Godfrey-Faussett P, Schaaf HS. 2009. High incidence of tuber-culosis among HIV-infected infants: evidence from a South African population-based study highlights the need for improved tuberculosis control strategies. Clin Infect Dis 48:108-114. https://doi.org/10.1086/595012.
38. Talbot EA, Perkins MD, Silva SF, Frothingham R. 1997. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clin Infect Dis 24:1139-1146. https://doi.org/10.1086/513642.
39. Gengenbacher M, Nieuwenhuizen N, Vogelzang A, Liu H, Kaiser P, Schuerer S, Lazar D, Wagner I, Mollenkopf HJ, Kaufmann SH. 2016. Deletion of nuoG from the vaccine candidate Mycobacterium bovis BCG ΔureC:hly improves protection against tuberculosis. mBio 7:e00679-16. https://doi.org/10.1128/mBio.00679-16.
40. Velmurugan K, Grode L, Chang R, Fitzpatrick ML, Laddy D, Hokey D, Derrick S, Morris S, McCown D, Kidd R, Gengenbacher M, Eisele B, Kaufmann SH, Fulkerson J, Brennan MJ. 2013. Nonclinical development of BCG replacement vaccine candidates. Vaccines (Basel) 1:120-138. https://doi.org/10.3390/vaccines1020120.
41. Grode L, Ganoza CA, Brohm C, Weiner J, III, Eisele B, Kaufmann SH. 2013. Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. Vaccine 31:1340-1348. https://doi.org/10.1016/j.vaccine.2012.12.053.
42. + T cells: differentiation, phenotype and role in inflammatory disease. Immunol Lett 178:20-26. https://doi.org/10.1016/j.imlet.2016.05.001.
43. da Silva MV, Tiburcio MG, Machado JR, Silva DA, Rodrigues DB, Ro-drigues V, Oliveira CJ. 2015. Complexity and controversies over the cytokine profiles of T helper cell subpopulations in tuberculosis. J Im-munol Res 2015:639107. https://doi.org/10.1155/2015/639107.
44. Hamada H, Garcia-Hernandez ML, Reome JB, Misra SK, Strutt TM, Mc-Kinstry KK, Cooper AM, Swain SL, Dutton RW. 2009. Tc17, a unique subset of CD8 T cells that can protect against lethal influenza challenge. J Immunol 182:3469-3481. https://doi.org/10.4049/jimmunol.0801814.
45. + T cells protect against influenza infection. J Im-munol 190:296-306. https://doi.org/10.4049/jimmunol.1200571.
46. + T cells for potent protection against mucosal Brucella melitensis challenge. Immunol Cell Biol 94:496-508. https://doi.org/10.1038/icb.2016.5.
47. Ravichandran J, Jackson RJ, Trivedi S, Ranasinghe C. 2015. IL-17A ex-pression in HIV-specific CD8 T cells is regulated by IL-4/IL-13 following HIV-1 prime-boost immunization. J Interferon Cytokine Res 35:176-185. https://doi.org/10.1089/jir.2014.0078.
48. Anonymous. 1994. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. Pediatrics 94:558-565.
49. DuPreez K Hesseling AC, Mandalakas AM, Marais BJ, Schaaf HS. 2011. Opportunities for chemoprophylaxis in children with culture-confirmed tuberculosis. Ann Trop Paediatr 31:301-310. https://doi.org/10.1179/1465328111Y.0000000035.
50. Fan L, Xiao H, Mai G, Su B, Ernst J, Hu Z. 2015. Impaired Mycobacterium tuberculosis antigen-specific IFN-gamma response without IL-17 enhancement in patients with severe cavitary pulmonary tuberculosis. PLoS One 10:e0127087. https://doi.org/10.1371/journal.pone.0127087.
51. Nunnari G, Pinzone MR Vancheri C, Palermo F, Cacopardo B. 2013. Interferon-gamma and interleukin-17 production from PPD-stimulated PBMCs of patients with pulmonary tuberculosis. Clin Invest Med 36: E64-E71.
52. Kozakiewicz L, Chen Y, Xu J, Wang Y, Dunussi-Joannopoulos K, Ou Q, Flynn JL, Porcelli SA, Jacobs WR, Jr, Chan J. 2013. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vac-cination by modulating the interleukin-17 response. PLoS Pathog 9:e1003472. https://doi.org/10.1371/journal.ppat.1003472.
53. + T cells in active disease. Eur J Immunol 43:939-948. https://doi.org/10.1002/eji.201243090.
54. Caccamo N, Guggino G, Meraviglia S, Gelsomino G, Di CP, Titone L, Bocchino M, Galati D, Matarese A, Nouta J, Klein MR, Salerno A, Sanduzzi A, Dieli F, Ottenhoff TH. 2009. Analysis of Mycobacterium tuberculosis-specific CD8 T cells in patients with active tuberculosis and in individuals with latent infection. PLoS One 4:e5528. https://doi.org/10.1371/journal.pone.0005528.
55. + T cell expansions arise during tuberculosis because of TCR selection. PLoS Pathog 11:e1004849. https://doi.org/10.1371/journal.ppat.1004849.
56. Kagina BM, Abel B, Scriba TJ, Hughes EJ, Keyser A, Soares A, Gamieldien H, Sidibana M, Hatherill M, Gelderbloem S, Mahomed H, Hawkridge A, Hussey G, Kaplan G, Hanekom WA, other members of the South African Tuberculosis Vaccine Initiative. 2010. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis, following BCG vaccination of newborns. Am J Respir Crit Care Med 182:1073-1079. https://doi.org/10.1164/rccm.201003-0334OC
57. Qiu Z, Zhang M, Zhu Y, Zheng F, Lu P, Liu H, Graner MW, Zhou B, Chen X. 2012. Multifunctional CD4 T cell responses in patients with active tuberculosis. Sci Rep 2:216. https://doi.org/10.1038/srep00216.
58. Anderson ST, Kaforou M, Brent AJ, Wright VJ, Banwell CM, Chagaluka G, Crampin AC, Dockrell HM, French N, Hamilton MS, Hibberd ML, Kern F, Langford PR, Ling L, Mlotha R Ottenhoff TH, Pienaar S, Pillay V, Scott JA, Twahir H, Wilkinson RJ, Coin LJ, Heyderman RS, Levin M, Eley B, ILULU Consortium, KIDS TB Study Group. 2014. Diagnosis of childhood tuber-culosis and host RNA expression in Africa. N Engl J Med 370:1712-1723. https://doi.org/10.1056/NEJMoa1303657.
59. Cliff JM, Lee JS, Constantinou N, Cho JE, Clark TG, Ronacher K, King EC, Lukey PT, Duncan K, Van Helden PD, Walzl G, Dockrell HM. 2013. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. J Infect Dis 207:18-29. https://doi.org/10.1093/infdis/jis499.
60. Kaufmann SH. 2013. Tuberculosis vaccines: time to think about the next generation. Semin Immunol 25:172-181. https://doi.org/10.1016/j.smim.2013.04.006.
61. Ottenhoff TH, Kaufmann SH. 2012. Vaccines against tuberculosis: where are we and where do we need to go? PLoS Pathog 8:e1002607. https://doi.org/10.1371/journal.ppat.1002607.
62. Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG. 2014. Tuberculosis vaccines and prevention of infection. Microbiol Mol Biol Rev 78:650-671. https://doi.org/10.1128/MMBR.00021-14.
63. Groschel MI, Prabowo SA, Cardona PJ, Stanford JL, van der Werf TS. 2014. Therapeutic vaccines for tuberculosis: a systematic review. Vaccine 32: 3162-3168. https://doi.org/10.1016/j.vaccine.2014.03.047.
64. World Health Organization. 2013. WHO Expert Committee on Biological Standardization-Annex 3: recommendations to assure the quality, safety and efficacy of BCG vaccines. Technical report series 979 2013. World Health Organization, Geneva, Switzerland.
65. U.S. Department of Health and Human Services. 2009. Division of AIDS table for grading the severity of adult and pediatric adverse events, version 1.0. U.S. Department of Health and Human Services, Washington, DC. http://www.mtnstopshiv.org/sites/default/files/attachments/DAIDS-AE-GradingTable-ClarificationAug2009-Final-[1].pdf.
66. Hanekom WA, Hughes J, Mavinkurve M, Mendillo M, Watkins M, Gamieldien H, Gelderbloem SJ, Sidibana M, Mansoor N, Davids V, Murray RA, Hawkridge A, Haslett PA, Ress S, Hussey GD, Kaplan G. 2004. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J Immunol Methods 291:185-195. https://doi.org/10.1016/j.jim.2004.06.010.
67. Smyth GK. 2005. limma: linear models for microarray data, p 397-420. In Gentleman R, Carey VJ, Huber W, Irizarry RA, Dudoit S (ed), Bioinformat-ics and computational biology solutions using R bioconductor. Springer, New York, NY.
68. Weiner J, III, Domaszewska T. 2016. tmod: an R package for general and multivariate enrichment analysis. PeerJ Preprints 4:e2420v1.
69. World Medical Association. 2013. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310: 2191-2194. https://doi.org/10.1001/jama.2013.281053.